TRAXV MEXC RealStocks
Own real TRAXV shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-14 14:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
First Tracks Biotherapeutics, Inc. (TRAXV) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- | |
-- |
First Tracks Biotherapeutics, Inc. (TRAXV) last closed at $-- as of --, -- from the previous close of $--.
During the latest regular trading session, TRAXV traded between $-- and $--, with a volume of -- shares. The closing price was -- and --.
Over the past seven days, First Tracks Biotherapeutics, Inc. (TRAXV) moved from $24.20 to $22.51, representing a decline of 6.98% ($1.69).
The stock traded between $21.77 and $26.80 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7.90 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
| Exchange | NASDAQ |
Eligible investors can buy real shares of First Tracks Biotherapeutics, Inc. (TRAXV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TRAXV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TRAXV shares and USD.
TRAXV Shares to USD
1.00 TRAXV shares = 0 USD
Calculations are estimates based on the latest available price and are for reference only.